Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
4.960
-0.200 (-3.88%)
Mar 20, 2026, 4:00 PM EDT - Market closed
Savara Employees
Savara had 70 employees as of December 31, 2025. The number of employees increased by 11 or 18.64% compared to the previous year.
Employees
70
Change (1Y)
11
Growth (1Y)
18.64%
Revenue / Employee
n/a
Profits / Employee
-$1,697,671
Market Cap
1.02B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 700 |
| AbCellera Biologics | 562 |
| Pharming Group | 404 |
| Geron | 258 |
| Inhibrx Biosciences | 161 |
| Septerna | 130 |
| ORIC Pharmaceuticals | 104 |
| ArriVent BioPharma | 77 |
SVRA News
- 8 days ago - Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Business Wire
- 15 days ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 17 days ago - Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
- 4 weeks ago - Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 5 weeks ago - Savara Announces New Employment Inducement Grant - Business Wire
- 6 weeks ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
- 7 weeks ago - Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
- 2 months ago - Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha